<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="translate">
            <roleset id="translate.01" name="molecular event of producing genetic product called protein&#x0A;" wordnet="10">
                <roles>
                    <role n="0" descr="resultant product &#x09;&#x09;&#x09;// protein //&#x0A;" />
                    <role n="1" descr="source &#x09;&#x09;&#x09;&#x09;&#x09;// mRNA, transcript // &#x0A;" />
                    <role n="2" descr="location as tissue, cell, vitro&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A correct translation to vitro of recombinant DNA-bound clones with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells has been translated.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Alternative deposition of exon 4 results in transcribed to be translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while deposition of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Alternative splicing of exon 4 results in a transcript that can be translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Alternative splicing of exon 4 results in a transcript that has been translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Alternative splicing of exon 4 results in a transcript that may have been translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Alternative splicing of exon 4 results in a transcription being translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Alternative splicing of exon 4 results in a transcription likely to be translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Alternative splicing of exon 4 results in a transcription probably translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Alternative splicing of exon 4 results in a transcription that can be translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Alternative splicing of exon 4 results in a transcription that is observed to be translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Alternative splicing of exon 4 results in a transcription that translated to a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Alternative splicing of exon 4 results in a transcription translated to a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Deposition of a truncated C-terminal protein translated the first, second, and third transmembrane domains, while deposition of one of the 3 and 4 exons would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                </example>
                <example src="EGRAM" no="13">
                    <text>ISGF3 blood cells that is observed to be adequately translated into vitro of A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 blood cells purified from HeLa cells.</text>
                    <arg n="0">ISGF3 blood cells</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>ISGF3 gamma adequately translated to A2 clones (recombinant) binds DNA to an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>ISGF3 gamma can be correctly translated into vitro from A1 clones (recombinant) bound to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>ISGF3 gamma can be translated into vitro from A1 clones (recombinant) bound to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>ISGF3 gamma can be translated into vitro from clones bound to the DNA recombinant with an indistinguishable specificity of ISGF3 gamma purified from the HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>ISGF3 gamma can be translated into vitro from recombinant DNA-binding clones with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>ISGF3 gamma correctly translated into vitro of recombinant clones that bind to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>ISGF3 gamma has been correctly translated into vitro of clones bound to the DNA recombinant with an indistinguishable specificity of ISGF3 gamma purified from the HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>ISGF3 gamma has been observed to translated correctly into vitro from recombinant clones bound to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>ISGF3 gamma has been observed to translated into vitro from recombinant clones bound to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>ISGF3 gamma has been shown to be correctly translated into vitro of recombinant DNA-bound clones with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>ISGF3 gamma has been shown to translated correctly into vitro from A1 clones (recombinant) bound to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>ISGF3 gamma has been shown to translated into vitro from recombinant clones bound to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>ISGF3 gamma has been translated into vitro from clones linked to the DNA recombinant with an indistinguishable specificity of ISGF3 gamma purified from the HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>ISGF3 gamma is able to be adequately translated into vitro from recombinant DNA-bound clones with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>ISGF3 gamma is able to be properly translated into vitro from clones bound to recombinant DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>ISGF3 gamma is able to be translated into vitro from recombinant DNA-bound clones with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>ISGF3 gamma is correctly translated into vitro from A1 clones (recombinant) bound to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>ISGF3 gamma is likely to be correctly translated into vitro from A1 clones (recombinant) bound to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>ISGF3 gamma is likely to be translated to vitro from recombinant DNA-bound clones with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>ISGF3 gamma is shown to translated into vitro from recombinant clones attached to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>ISGF3 gamma may have been correctly translated to vitro of recombinant DNA-binding clones with an indistinguishable specificity of ISGF3 gamma purified HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>ISGF3 gamma that can be adequately translated into vitro of A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 gamma purified HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>ISGF3 gamma that can be correctly translated into A2 clones (recombinant) binds DNA to an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>ISGF3 gamma that can be translated into vitro of A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>ISGF3 gamma that has been adequately translated into vitro of A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 gamma purified HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>ISGF3 gamma that has been translated into vitro of A1 clones (recombinant) binds DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>ISGF3 gamma that is able to be translated adequately into vitro of A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>ISGF3 gamma that is able to be translated into vitro of A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>ISGF3 gamma that is adequately translated into vitro of A1 clones (recombinant) binds DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>ISGF3 gamma that is likely to be translated into vitro of A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>ISGF3 gamma that may have been adequately translated into vitro of A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>ISGF3 gamma that may have been translated into vitro of A1 clones (recombinant) bind DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>ISGF3 gamma that may have been translated into vitro of A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>ISGF3 gamma that will be translated into vitro of A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>ISGF3 gamma translated into vitro from recombinant DNA-binding clones with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>ISGF3 gamma was correctly translated into vitro from A1 clones (recombinant) bound to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>ISGF3 gamma was properly translated into vitro from clones linked to the DNA recombinant with an indistinguishable specificity of ISGF3 gamma purified from the HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>ISGF3 gamma was translated into vitro from A1 clones (recombinants) that bind to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>ISGF3 gamma was translated into vitro of clones bound to the DNA recombinant with an indistinguishable specificity of ISGF3 gamma purified from the HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>ISGF3 gamma which can be correctly translated into vitro clones recombinant link the DNA to an indistinguishable specificity of the ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>ISGF3 gamma which has been translated into vitro of A1 clones (recombinant) binds DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>ISGF3 gamma which is able to be properly translated into vitro clones recombinant bind DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>ISGF3 gamma which is likely to be translated into vitro of A1 clones (recombinant) bind DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>ISGF3 gamma which is translated into vitro of A1 clones (recombinant) binds DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>ISGF3 gamma which translated into vitro from recombinant DNA-binding clones with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>ISGF3 gamma will be correctly translated into vitro from DNA A1 clones (recombinant) linked to an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>ISGF3 gamma will be translated into vitro from recombinant clones bound to DNA with an indistinguishable specificity of ISGF3 gamma purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gamma</arg>
                    <arg n="1">recombinant</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>ISGF3 gum that has been translated into vitro of A1 clones (recombinant) binds DNA with an indistinguishable specificity of ISGF3 gum purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gum</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>ISGF3 gum, which will be translated appropriately into vitro of A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 gum, purified from HeLa cells.</text>
                    <arg n="0">ISGF3 gum</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>ISGF3 snake that is observed to be translated into vitro of A1 clones (recombinant) binds DNA with an indistinguishable specificity of ISGF3 snake purified from HeLa cells.</text>
                    <arg n="0">ISGF3 snake</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>ISGF3 swab which has been shown to have been translated into vitro from A1 clones (recombinant) bind the DNA with an indistinguishable specificity of ISGF3 swab purified from HeLa cells.</text>
                    <arg n="0">ISGF3 swab</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>ISGF3 swab, which has been adequately translated into vitro of A1 clones (recombinant), binds DNA with an indistinguishable specificity of ISGF3 swab, purified from HeLa cells.</text>
                    <arg n="0">ISGF3 swab</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>ISGF3 swab, which has been properly translated into vitro of A1 clones (recombinant), binds DNA with an indistinguishable specificity of ISGF3 swab, purified from HeLa cells.</text>
                    <arg n="0">ISGF3 swab</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>It has been shown that a transcript, as our data have shown is efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>It has been shown that a transcript, as our data have shown is translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>It has been shown that more than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators were translated from open leing frameworks.</text>
                    <arg n="0">open leing frameworks</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>It has been shown that over 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators have been fully translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>It has been shown that translation, as our data showed is efficiently translated into a truncated C-terminal protein containing the first, second and third transmembrane domains, while splicing exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">translation, as our data showed</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>It has been shown that translation, as our data showed is translated into a truncated C-terminal protein containing the first, second and third transmembrane domains, while splicing exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">translation, as our data showed</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>It is likely that a transcript, as demonstrated by our data will be efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 will produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as demonstrated by our data</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>It is observed that a transcript, as demonstrated by our data is translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as demonstrated by our data</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>It is observed that translation, as demonstrated by our data is translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while splicing exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">translation, as demonstrated by our data</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of positive prokaryotic transcriptional regulators are translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of positive prokaryotic transcriptional regulators have been translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of positive prokaryotic transcriptional regulators will be translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators are able to be fully translated from open leing frameworks.</text>
                    <arg n="0">open leing frameworks</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators are fully translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators are likely to be fully translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators are likely to be translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators are observed to be completely translated from open frames.</text>
                    <arg n="0">open frames</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators are observed to be fully translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators are observed to be translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators can be fully translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators can be translated completely from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators can be translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic positive transcriptional regulators have the ability to be translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic transcriptional regulators have been fully translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic transcriptional regulators have been fully translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic transcriptional regulators have the ability to be fully translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic transcriptional regulators may have been fully translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic transcriptional regulators may have been translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>More than 100 proteins and polypeptides included in the ArC/XylS family of prokaryotic transcriptional regulators will be translated completely from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of pro-karyotic positive transcriptional regulators are likely to be translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of pro-karyotic positive transcriptional regulators have been translated completely from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of pro-karyotic positive transcriptional regulators may have been translated completely from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators are able to be translated completely from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators are able to be translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators are completely translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators are observed to be translated from open led frames.</text>
                    <arg n="0">open led frames</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators are translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators can be translated completely from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators can be translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators have been translated completely from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators have been translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators have the ability to be translated completely from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators have the ability to be translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators may have been translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators will be translated completely from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>More than 100 proteins and polypeptides that are included in the ArC/XylS family of prokaryotic positive transcriptional regulators will be translated from open leing frames.</text>
                    <arg n="0">open leing frames</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>Stat1 Y701F has been shown to be translated to vitro can also be dimerised to LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>Stat1 Y701F has been shown to translated into vitro can also be dimerized into the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>Stat1 Y701F that can be translated to vitro can also be dimerised to LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>Stat1 Y701F that can probably be translated into vitro can also be dimerized into LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>Stat1 Y701F that can probably be translated to vitro can also be dimerised into LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>Stat1 Y701F that has been shown to probably translated into vitro can also be dimerized into the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>Stat1 Y701F that has been translated into vitro can also dimer in the SGL2 of LMP2.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>Stat1 Y701F that has been translated to vitro can also be dimerised to LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>Stat1 Y701F that has probably been translated to vitro can also be dimerised into LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>Stat1 Y701F that is likely to be translated into vitro can also be dimerized into the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>Stat1 Y701F that is likely to be translated to vitro can also be dimerised to LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>Stat1 Y701F that is observed to be probably translated into vitro can also dimerize in the SGL2 of LMP2.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>Stat1 Y701F that is observed to be translated into vitro can also dimerize in the SGL2 of LMP2.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>Stat1 Y701F that probably translated into vitro can also be dimerised in the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>Stat1 Y701F that translated into vitro can also be dimerised to the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>Stat1 Y701F that will probably be translated into vitro can also be submerged into SGL2 LMP2.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>Stat1 Y701F that will probably be translated to vitro can also be dimerised into LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>Stat1 Y701F which can be translated into vitro can also be dimerized into the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>Stat1 Y701F which has been translated into vitro can also be dimerized into the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>Stat1 Y701F which has probably been translated into vitro can also be dimerized into LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>Stat1 Y701F which has probably translated into vitro can also be dimerised to the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>Stat1 Y701F which is observed to be translated into vitro can also be dimerized into SGL2 of LMP2.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>Stat1 Y701F which probably translated into vitro can also be dimerized into the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>Stat1 Y701F which translated to vitro can also be dimerized into LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>Stat1 Y701F which translated to vitro can also be dimerized into the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>Stat1 Y701F which translated to vitro can also be submerged to SGL2.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>Stat1 Y701F which was probably translated into vitro can also be dimerized into the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>Stat1 Y701F which was translated into vitro can also be dimerized into the LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>Stat1 Y701F which will probably be translated into vitro can also be submerged into LMP2 SGL2.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>Stat1 Y701F, which has probably been translated to vitro, can also be dimerised to LMP2 gas.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>Stat1 Y701F, which is able to be translated into vitro, can also dimer into SGL2.</text>
                    <arg n="0">Stat1 Y701F</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>Stat1, Estat1 Y701F, Estat1 N135, Estat1 N200 and Estat5/1, as our data show, are translated into vitro and partially purified into heparin-aminosis.</text>
                    <arg n="0">Stat1, Estat1 Y701F, Estat1 N135, Estat1 N200 and Estat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>Stat1, Estat1 Y701F, Estat1 N135, Estat1 N200 and Estat5/1, as our data show, can be translated into vitro and partially purified into heparin-amikanosis.</text>
                    <arg n="0">Stat1, Estat1 Y701F, Estat1 N135, Estat1 N200 and Estat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>Stat1, Estat1 Y701F, Estat1 N135, Estat1 N200 and Estat5/1, as our data show, can be translated to vitro and partially purified to heparin-acrose.</text>
                    <arg n="0">Stat1, Estat1 Y701F, Estat1 N135, Estat1 N200 and Estat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>Stat1, Estat1 Y701F, Estat1 N135, Estat1 N200 and Stat5/1, as our data show, has the ability to be translated to vitro and partially purified to heparin-astrose.</text>
                    <arg n="0">Stat1, Estat1 Y701F, Estat1 N135, Estat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 , as our data reveal, has been shown to translated into vitro and to partially purify into heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 , as our data reveal, have been translated into vitro and partially purified into heparin-astrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 , as our data reveal, is observed to translated into vitro and to partially purify into heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 are able to be translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 are likely to be translated into vitro and partially purified into heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 are likely to be translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 are observed to be properly translated into vitro are partially purified in heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 are observed to translated to vitro are partially purified in heparin-astroosa.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 are translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 are translated into vitro and partially purified into heparin-astroosis.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 can be translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 can be translated into vitro and partially purified into heparin-astroosis.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 can be translated into vitro and purified partially in heparin-astroose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 has been shown to translated into vitro and to partially purify into heparin-astroosa.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 has been shown to translated into vitro are partially purified in heparin-astroosa.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 has the ability to be translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 have been translated into vitro and purified partially in heparin-astroosa.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 have the ability to be translated into vitro and partially purified into heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 is observed to be translated into vitro and partially purified into heparin-astroosa.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 is observed to be translated into vitro and partially purified into heparin-astrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 may have been translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 may have been translated into vitro and partially purified into heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that are able to be translated adequately into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that are able to be translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that are adequately translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that are likely to be translated into vitro are partially purified in heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that are likely to be translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that are observed as being adequately translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="176">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that are observed to be translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="177">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that are properly translated into vitro are partially purified in heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="178">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that are translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="179">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that can be correctly translated into vitro are partially purified in heparin-astroosis.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="180">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that can be correctly translated into vitro are partially purified in heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="181">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that can be translated adequately into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="182">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that can be translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="183">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that can be translated into vitro are partially purified in heparin-astroosis.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="184">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that has been proven to be correctly translated to vitro are partially purified in heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="185">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that has been shown to be correctly translated into vitro are partially purified in heparin-astroosa.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="186">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that have been properly translated into vitro are partially purified in heparin-astrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="187">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that have been translated adequately into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="188">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that have been translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="189">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that have been translated into vitro are partially purified into heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="190">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that have the ability to be translated adequately into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="191">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that have the ability to be translated correctly into vitro are partially purified in heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="192">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that have the ability to be translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="193">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that have the ability to be translated into vitro are partially purified in heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="194">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that is likely to be correctly translated to vitro is partially purified into heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="195">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that may have been adequately translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="196">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that may have been correctly translated into vitro is partially purified in heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="197">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that may have been translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="198">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that may have been translated into vitro is partially purified in heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="199">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that translated into vitro are partially purified in heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="200">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that will be correctly translated into vitro are partially purified in heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="201">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that will be translated appropriately into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="202">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that will be translated into vitro are partially purified in heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="203">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 was partially translated in heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                </example>
                <example src="EGRAM" no="204">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 was translated to vitro and partially purified to heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="205">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 were translated into vitro and purified in part into heparin-astrous.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="206">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 which will be translated into vitro are partially purified into heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="207">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 will be translated into vitro and partially purified into heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="208">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 will be translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="209">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data reveal, is observed to translated into vitro and purify in part into heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="210">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, are able to be translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="211">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, are likely to be translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="212">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, are translated into vitro and partially purified into heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="213">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, can be translated into vitro and partially purified into heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="214">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, has the ability to be translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="215">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, is likely to be translated into vitro and partially purified into heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="216">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, may have been translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="217">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, was translated to vitro and partially purified in heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="218">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, were translated into vitro and partially purified into heparin-agarose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="219">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, will be translated into vitro and partially purified into heparin-acrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="220">
                    <text>Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, will be translated into vitro and partially purified into heparin-aminosis.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="221">
                    <text>The A0 blood cells (ISGF3) that are observed to be properly translated into vitro of A1 clones (recombinant) bind DNA with an indistinguishable specificity of A0 (ISGF3 blood cells) purified from HeLa cells.</text>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="222">
                    <text>The A0 snake (ISGF3) is observed to translated into vitro of the A1 clones (recombinant) binds DNA with an indistinguishable specificity of the A0 snake (ISGF3) purified from the HeLa cells.</text>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="223">
                    <text>The ArC/XylS family of positive prokaryotes transcriptional regulators includes more than 100 proteins and polypeptides that will be translated from open frames.</text>
                    <arg n="0">open frames</arg>
                </example>
                <example src="EGRAM" no="224">
                    <text>The ArC/XylS family of positive prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that are able to be translated from open led frames.</text>
                    <arg n="0">open led frames</arg>
                </example>
                <example src="EGRAM" no="225">
                    <text>The ArC/XylS family of positive prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that are likely to be translated from open frames.</text>
                    <arg n="0">open frames</arg>
                </example>
                <example src="EGRAM" no="226">
                    <text>The ArC/XylS family of positive prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that are observed to be translated from open frames.</text>
                    <arg n="0">open frames</arg>
                </example>
                <example src="EGRAM" no="227">
                    <text>The ArC/XylS family of positive prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that are observed to be translated from open led frames.</text>
                    <arg n="0">open led frames</arg>
                </example>
                <example src="EGRAM" no="228">
                    <text>The ArC/XylS family of positive prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that can be translated from open frames.</text>
                    <arg n="0">open frames</arg>
                </example>
                <example src="EGRAM" no="229">
                    <text>The ArC/XylS family of positive prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that can be translated from open leing frameworks.</text>
                    <arg n="0">open leing frameworks</arg>
                </example>
                <example src="EGRAM" no="230">
                    <text>The ArC/XylS family of positive prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that have the ability to be translated from open led frames.</text>
                    <arg n="0">open led frames</arg>
                </example>
                <example src="EGRAM" no="231">
                    <text>The ArC/XylS family of prokaryotic positive transcription regulators includes more than 100 proteins and polypeptides observed to be translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="232">
                    <text>The ArC/XylS family of prokaryotic positive transcription regulators includes more than 100 proteins and polypeptides that translated from open leing frameworks.</text>
                    <arg n="0">open leing frameworks</arg>
                </example>
                <example src="EGRAM" no="233">
                    <text>The ArC/XylS family of prokaryotic positive transcriptional regulators includes more than 100 proteins and polypeptides that are translated from aber reading tables.</text>
                    <arg n="0">aber reading tables</arg>
                </example>
                <example src="EGRAM" no="234">
                    <text>The ArC/XylS family of prokaryotic positive transcriptional regulators includes more than 100 proteins and polypeptides that have been shown to be translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="235">
                    <text>The ArC/XylS family of prokaryotic positive transcriptional regulators includes more than 100 proteins and polypeptides that have been translated from aber reading tables.</text>
                    <arg n="0">aber reading tables</arg>
                </example>
                <example src="EGRAM" no="236">
                    <text>The ArC/XylS family of prokaryotic positive transcriptional regulators includes more than 100 proteins and polypeptides that have been translated from open leing frameworks.</text>
                    <arg n="0">open leing frameworks</arg>
                </example>
                <example src="EGRAM" no="237">
                    <text>The ArC/XylS family of prokaryotic positive transcriptional regulators includes more than 100 proteins and polypeptides translated from aber reading tables.</text>
                    <arg n="0">aber reading tables</arg>
                </example>
                <example src="EGRAM" no="238">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that are likely to be translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="239">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that are translated from open leing frameworks.</text>
                    <arg n="0">open leing frameworks</arg>
                </example>
                <example src="EGRAM" no="240">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that are translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="241">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that can be translated from open leing frameworks.</text>
                    <arg n="0">open leing frameworks</arg>
                </example>
                <example src="EGRAM" no="242">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that can be translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="243">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that have been translated from open leing frameworks.</text>
                    <arg n="0">open leing frameworks</arg>
                </example>
                <example src="EGRAM" no="244">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that have been translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="245">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that have the ability to be translated from open led frames.</text>
                    <arg n="0">open led frames</arg>
                </example>
                <example src="EGRAM" no="246">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that may have been translated from open leing frameworks.</text>
                    <arg n="0">open leing frameworks</arg>
                </example>
                <example src="EGRAM" no="247">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that may have been translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="248">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides that will be translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="249">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators includes more than 100 proteins and polypeptides translated from open lee frameworks.</text>
                    <arg n="0">open lee frameworks</arg>
                </example>
                <example src="EGRAM" no="250">
                    <text>The ArC/XylS family of prokaryotic transcriptional regulators translated more than 100 proteins and polypeptides that are shown translated from open reading frameworks.</text>
                    <arg n="0">open reading frameworks</arg>
                </example>
                <example src="EGRAM" no="251">
                    <text>The Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1 that is likely to be correctly translated into vitro is partially purified in heparin-astroosa.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="252">
                    <text>The Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1, as our data show, may have been translated into vitro and partially purified into heparin-astrose.</text>
                    <arg n="0">Stat1, Stat1 Y701F, Stat1 N135, Stat1 N200 and Stat5/1</arg>
                    <arg n="2">vitro</arg>
                </example>
                <example src="EGRAM" no="253">
                    <text>The alternative deposition of exon 4 results in transcribed that can be translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the deposition of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="254">
                    <text>The alternative deposition of exon 4 results in transcribed that may have been translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the deposition of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="255">
                    <text>The alternative deposition of exon 4 results in transcribed that was translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the deposition of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="256">
                    <text>The alternative deposition of exon 4 results in transcribed that will be translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the deposition of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="257">
                    <text>The alternative deposition of exon 4 results in transcribed translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the deposition of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="258">
                    <text>The alternative deposition of exon 4 results in transcribed which is translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the deposition of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="259">
                    <text>The alternative deposition of exon 4 results in translation probably translated into a truncated C-terminal protein containing the first, second and third transmembrane domains, while the deposition of exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">translation</arg>
                </example>
                <example src="EGRAM" no="260">
                    <text>The deposition of a culler spoon solution translated the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass, the ass.</text>
                </example>
                <example src="EGRAM" no="261">
                    <text>The deposition of a solution of exon 4 splicing results in transcribed that can be translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the deposition of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="262">
                    <text>The deposition of a solution of exon 4 splicing results in transcribed that proved to be translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the deposition of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="263">
                    <text>The deposition of a truncated C-terminal protein translated the first, second and third transmembrane domains, while the deposition of exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                </example>
                <example src="EGRAM" no="264">
                    <text>The deposition of a truncated C-terminal protein translated the first, second and third transmembrane domains, while the deposition of one of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                </example>
                <example src="EGRAM" no="265">
                    <text>The deposition of a truncated C-terminal protein translated the first, second and third transmembranous domains, while the deposition of one of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                </example>
                <example src="EGRAM" no="266">
                    <text>The deposition of a truncated C-terminal protein translated the first, second, and third transmembrane domains, while deposition of one of the 3 and 4 exons would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                </example>
                <example src="EGRAM" no="267">
                    <text>The deposition of an alternative spodosis solution of exon 4 results in a transcription that can be translated into a truncated C-terminal protein containing the first, second and third transmembranous domains, while the deposition of exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second and third transmembranous domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="268">
                    <text>The deposition of an exon 4 splicing solution results in transcribed that can be translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while deposition of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="269">
                    <text>The deposition of an exon 4 spoon solution results in transcribed that was translated into a truncated C-terminal protein containing the first, second and third transmembrane domains, while the deposition of exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="270">
                    <text>The deposition of an exon 4 spoon solution results in translation that was translated into a truncated C-terminal protein containing the first, second and third transmembranous domains, while the deposition of exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second and third transmembranous domains</arg>
                    <arg n="1">translation</arg>
                </example>
                <example src="EGRAM" no="271">
                    <text>This mutant is able to be translated into the presence of C-terminal SBP, and as shown in Figure 6C, reading when the AUGA element is excluded is not detectable, indicating that the stimulating effect is completely 3 UTR dependent.</text>
                    <arg n="0">This mutant</arg>
                </example>
                <example src="EGRAM" no="272">
                    <text>This mutant is likely to be translated into the presence of C-terminal SBP, and as shown in Figure 6C, reading the AUGA element is not detectable, indicating that the stimulatory effect is completely 3 UTR dependent.</text>
                    <arg n="0">This mutant</arg>
                </example>
                <example src="EGRAM" no="273">
                    <text>This mutant is observed to be translated into the presence of C-terminal SBP, and as shown in Figure 6C, reading when the AUGA element is excluded is not detectable, indicating that the stimulatory effect is completely 3 UTR dependent.</text>
                    <arg n="0">This mutant</arg>
                </example>
                <example src="EGRAM" no="274">
                    <text>This mutant, as revealed in our study, can be translated into the presence of C-terminal SBP, and as shown in Figure 6C, reading the AUGA element is not detectable, indicating that the stimulatory effect is completely 3 UTR dependent.</text>
                    <arg n="0">This mutant</arg>
                </example>
                <example src="EGRAM" no="275">
                    <text>This mutant, as revealed in our study, has been shown to be translated into the presence of C-terminal SBP, and as shown in Figure 6C, reading the AUGA element is not detectable, indicating that the stimulatory effect is totally 3 UTR dependent.</text>
                    <arg n="0">This mutant</arg>
                </example>
                <example src="EGRAM" no="276">
                    <text>This mutant, as revealed in our study, is able to be translated into the presence of PAS-C-terminal2, and as shown in Figure 6C, reading when the AUGA element is excluded is not detectable, indicating that the stimulating effect is totally 3 UTR dependent.</text>
                    <arg n="0">This mutant</arg>
                </example>
                <example src="EGRAM" no="277">
                    <text>This mutant, as revealed in our study, is translated into the presence of C-terminal SBP, and as shown in Figure 6C, reading the AUGA element is not detectable, indicating that the stimulatory effect is totally 3 UTR dependent.</text>
                    <arg n="0">This mutant</arg>
                </example>
                <example src="EGRAM" no="278">
                    <text>This mutant, as revealed in our study, will be translated into the presence of C-terminal SBP, and as shown in Figure 6C, reading the AUGA element is not detectable, indicating that the stimulatory effect is totally 3 UTR dependent.</text>
                    <arg n="0">This mutant</arg>
                </example>
                <example src="EGRAM" no="279">
                    <text>Transcription, as our data have shown can be efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">Transcription, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="280">
                    <text>Transcription, as our data have shown is efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">Transcription, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="281">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that can be successfully translated into reticulocyte forms.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte forms</arg>
                </example>
                <example src="EGRAM" no="282">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that can be successfully translated into reticulocyte shales.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte shales</arg>
                </example>
                <example src="EGRAM" no="283">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that can be translated into lysates reticulocytes.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="284">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that can be translated into reticulocyte forms.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte forms</arg>
                </example>
                <example src="EGRAM" no="285">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that could have been successfully translated into reticulocyte shaking.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte shaking</arg>
                </example>
                <example src="EGRAM" no="286">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that could have been translated into reticulocyte shales.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte shales</arg>
                </example>
                <example src="EGRAM" no="287">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that is able to be translated into lysates reticulocytes.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="288">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that is observed to be translated into lysates reticulocytes.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="289">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that may have been successfully translated into lysates reticulocytes.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="290">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that may have been translated into lysates reticulocytes.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="291">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that proved to be translated into lysates reticulocytes.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="292">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that translated into reticulocyte forms.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte forms</arg>
                </example>
                <example src="EGRAM" no="293">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that was observed to be successfully translated into lysates reticulocytes.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="294">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that was translated into lysates reticulocytes.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="295">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that will be translated into lysates reticulocytes.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="296">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that will be translated into reticulocyte dissertations.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte dissertations</arg>
                </example>
                <example src="EGRAM" no="297">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that will probably be successfully translated into with shading of reticulocytes.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">with shading of reticulocytes</arg>
                </example>
                <example src="EGRAM" no="298">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein that will probably be translated into lysates reticulocytes.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="299">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein which has been shown to be successfully translated into reticulocyte shales.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte shales</arg>
                </example>
                <example src="EGRAM" no="300">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein which has been successfully translated into reticulocyt lysates.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyt lysates</arg>
                </example>
                <example src="EGRAM" no="301">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein which has been translated into reticulocyt lysates.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyt lysates</arg>
                </example>
                <example src="EGRAM" no="302">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein which is likely to be successfully translated into reticulocyte shading.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte shading</arg>
                </example>
                <example src="EGRAM" no="303">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein which is observed to be successfully translated into reticulocyte shales.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte shales</arg>
                </example>
                <example src="EGRAM" no="304">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein which is observed to be translated into reticulocyte liabilities.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte liabilities</arg>
                </example>
                <example src="EGRAM" no="305">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein which is successfully translated into reticulocyte shales.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte shales</arg>
                </example>
                <example src="EGRAM" no="306">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein which translated into reticulocyte shales.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte shales</arg>
                </example>
                <example src="EGRAM" no="307">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein which will be successfully translated into reticulocyte shales.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte shales</arg>
                </example>
                <example src="EGRAM" no="308">
                    <text>We also report the first definitive incorporation of Sec into a selenoprotein which will probably be translated into reticulocyte cells.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte cells</arg>
                </example>
                <example src="EGRAM" no="309">
                    <text>We also report the first definitive incorporation of Sec into selenoprotein that is able to be successfully translated into lysates reticulocytes.</text>
                    <arg n="0">selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="310">
                    <text>We also report the first definitive incorporation of Sec into selenoprotein that was translated into lysates reticulocytes.</text>
                    <arg n="0">selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="311">
                    <text>We also report the first definitive incorporation of Sec into selenoprotein that will be successfully translated into reticulocyte forms.</text>
                    <arg n="0">selenoprotein</arg>
                    <arg n="2">reticulocyte forms</arg>
                </example>
                <example src="EGRAM" no="312">
                    <text>We also report the first definitive incorporation of Sec into selenoprotein which has been successfully translated into reticulocyte cells.</text>
                    <arg n="0">selenoprotein</arg>
                    <arg n="2">reticulocyte cells</arg>
                </example>
                <example src="EGRAM" no="313">
                    <text>We also report the first definitive incorporation of Sec into selenoprotein which is able to be successfully translated into lysates reticulocytes.</text>
                    <arg n="0">selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="314">
                    <text>We also report the first definitive incorporation of Sec into selenoprotein which is successfully translated into reticulocyte forms.</text>
                    <arg n="0">selenoprotein</arg>
                    <arg n="2">reticulocyte forms</arg>
                </example>
                <example src="EGRAM" no="315">
                    <text>We also report the first definitive incorporation of Sec into selenoprotein which was successfully translated into lysates reticulocytes.</text>
                    <arg n="0">selenoprotein</arg>
                    <arg n="2">lysates reticulocytes</arg>
                </example>
                <example src="EGRAM" no="316">
                    <text>We also report the first definitive incorporation of Sec into selenoprotein which was successfully translated into lysed by reticulocytes.</text>
                    <arg n="0">selenoprotein</arg>
                    <arg n="2">lysed by reticulocytes</arg>
                </example>
                <example src="EGRAM" no="317">
                    <text>We also reported the first definitive incorporation of Sec into a selenoprotein which was shown to be translated into reticulocyte silates.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte silates</arg>
                </example>
                <example src="EGRAM" no="318">
                    <text>We also reported the first definitive incorporation of Sec into a selenoprotein which was successfully translated into reticulocyte shales.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte shales</arg>
                </example>
                <example src="EGRAM" no="319">
                    <text>We also reported the first definitive incorporation of Sec into a selenoprotein which was translated into reticulocyte dissertations.</text>
                    <arg n="0">a selenoprotein</arg>
                    <arg n="2">reticulocyte dissertations</arg>
                </example>
                <example src="EGRAM" no="320">
                    <text>a transcript, as our data have shown can be efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="321">
                    <text>a transcript, as our data have shown can be translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="322">
                    <text>a transcript, as our data have shown has been translated efficiently into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="323">
                    <text>a transcript, as our data have shown has been translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="324">
                    <text>a transcript, as our data have shown is likely to be translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="325">
                    <text>a transcript, as our data have shown may have been efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="326">
                    <text>a transcript, as our data have shown may have been translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="327">
                    <text>a transcript, as our data have shown translated to a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="328">
                    <text>a transcript, as our data have shown was efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="329">
                    <text>a transcript, as our data have shown was translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="330">
                    <text>a transcript, as our data have shown will be translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 will produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcript, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="331">
                    <text>a transcription can be efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="332">
                    <text>a transcription has been efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="333">
                    <text>a transcription has been shown to translated efficiently to a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="334">
                    <text>a transcription is able to be efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="335">
                    <text>a transcription is efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="336">
                    <text>a transcription is likely to be efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="337">
                    <text>a transcription is observed to be efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="338">
                    <text>a transcription may have been efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="339">
                    <text>a transcription was efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 would produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="340">
                    <text>a transcription will be efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing of exons 3 and 4 will produce a protein with five membrane domains but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">a transcription</arg>
                </example>
                <example src="EGRAM" no="341">
                    <text>this mutant , as our study reveals, can be translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="342">
                    <text>this mutant , as our study reveals, may have been translated in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="343">
                    <text>this mutant , as our study reveals, will be translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="344">
                    <text>this mutant can be efficiently translated into the presence of PAS-C-terminal2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="345">
                    <text>this mutant can be translated efficiently in the presence of C-terminal SBP, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is completely dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="346">
                    <text>this mutant can be translated efficiently in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is completely dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="347">
                    <text>this mutant can be translated efficiently in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="348">
                    <text>this mutant can be translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="349">
                    <text>this mutant has been shown to translated efficiently in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is completely dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="350">
                    <text>this mutant has been shown to translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="351">
                    <text>this mutant has been translated efficiently in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is completely dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="352">
                    <text>this mutant has been translated in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="353">
                    <text>this mutant is able to be efficiently translated in the presence of PAS-C-terminal2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="354">
                    <text>this mutant is able to be translated efficiently in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="355">
                    <text>this mutant is able to be translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="356">
                    <text>this mutant is efficiently translated in the presence of terminal C SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="357">
                    <text>this mutant is efficiently translated into the presence of terminal C PAS2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="358">
                    <text>this mutant is likely to be efficiently translated in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="359">
                    <text>this mutant is likely to be translated efficiently in the presence of PAS-C, and as can be seen in Figure 6C, no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="360">
                    <text>this mutant is likely to be translated in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="361">
                    <text>this mutant is observed to translated efficiently in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is completely dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="362">
                    <text>this mutant is observed to translated efficiently in the presence of PAS-C, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is completely dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="363">
                    <text>this mutant is observed to translated the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulating effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="364">
                    <text>this mutant may have been translated efficiently in the presence of C-terminal SBP, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is completely dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="365">
                    <text>this mutant may have been translated efficiently in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is completely dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="366">
                    <text>this mutant may have been translated in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="367">
                    <text>this mutant may have been translated into the presence of C-terminal SAP, and as shown in Figure 6C, no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="368">
                    <text>this mutant translated into the presence of C-terminal SBP, and as shown in Figure 6C, no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="369">
                    <text>this mutant translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="370">
                    <text>this mutant was efficiently translated into the presence of PAS-C-terminal2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is completely dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="371">
                    <text>this mutant was shown to be effective in the presence of PAS-C, and as shown in Figure 6C, no reader can be detected when the AUGA element is removed, translated that the stimulatory effect is completely dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="372">
                    <text>this mutant was translated into the presence of C-terminal SAP, and as shown in Figure 6C, no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="373">
                    <text>this mutant was translated to the presence of C-terminal SBP, and as shown in Figure 6C, no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="374">
                    <text>this mutant will be translated efficiently in the presence of C-terminal SBP, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is completely 3 UTR dependent.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="375">
                    <text>this mutant will be translated efficiently in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is fully 3 UTR dependent.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="376">
                    <text>this mutant will be translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="377">
                    <text>this mutant will be translated to the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="378">
                    <text>this mutant, as our study reveals, can be translated to the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="379">
                    <text>this mutant, as our study reveals, is likely to be translated in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is fully dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="380">
                    <text>this mutant, as our study reveals, may have been translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="381">
                    <text>this mutant, as revealed by our study, can be translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is fully dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="382">
                    <text>this mutant, as revealed by our study, has been shown to translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is fully dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="383">
                    <text>this mutant, as revealed by our study, has been translated in the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is fully dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="384">
                    <text>this mutant, as revealed by our study, is able to be translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="385">
                    <text>this mutant, as revealed by our study, is observed to translated into the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is fully dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="386">
                    <text>this mutant, as revealed by our study, is observed to translated the presence of C-terminal SBP2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="387">
                    <text>this mutant, as revealed by our study, translated into the presence of C-terminal SBP, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulating effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="388">
                    <text>this mutant, as revealed by our study, was translated into the presence of PAS-C-terminal2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="389">
                    <text>this mutant, as revealed in our study, is likely to be translated into the presence of PAS-C-terminal2, and as shown in Figure 6C no reader can be detected when the AUGA element is removed, indicating that the stimulatory effect is totally dependent on 3 UTR.</text>
                    <arg n="0">this mutant</arg>
                </example>
                <example src="EGRAM" no="390">
                    <text>transcribed can be efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing outside exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">transcribed</arg>
                </example>
                <example src="EGRAM" no="391">
                    <text>transcription, as our data show can be translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show</arg>
                </example>
                <example src="EGRAM" no="392">
                    <text>transcription, as our data show can be translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show</arg>
                </example>
                <example src="EGRAM" no="393">
                    <text>transcription, as our data show is translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show</arg>
                </example>
                <example src="EGRAM" no="394">
                    <text>transcription, as our data show may have been translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show</arg>
                </example>
                <example src="EGRAM" no="395">
                    <text>transcription, as our data show was efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show</arg>
                </example>
                <example src="EGRAM" no="396">
                    <text>transcription, as our data show was translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show</arg>
                </example>
                <example src="EGRAM" no="397">
                    <text>transcription, as our data show will be translated efficiently into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show</arg>
                </example>
                <example src="EGRAM" no="398">
                    <text>transcription, as our data show will be translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show</arg>
                </example>
                <example src="EGRAM" no="399">
                    <text>transcription, as our data show, can be efficiently translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show,</arg>
                </example>
                <example src="EGRAM" no="400">
                    <text>transcription, as our data show, is likely to be translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show,</arg>
                </example>
                <example src="EGRAM" no="401">
                    <text>transcription, as our data show, may have been efficiently translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show,</arg>
                </example>
                <example src="EGRAM" no="402">
                    <text>transcription, as our data show, will be efficiently translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data show,</arg>
                </example>
                <example src="EGRAM" no="403">
                    <text>transcription, as our data showed, is a C-terminal truncated protein translated the first, second and third transmembraned domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="1">transcription, as our data showed</arg>
                </example>
                <example src="EGRAM" no="404">
                    <text>transcription, as our data showed, is able to be efficiently translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data showed</arg>
                </example>
                <example src="EGRAM" no="405">
                    <text>transcription, as our data showed, is able to be translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data showed</arg>
                </example>
                <example src="EGRAM" no="406">
                    <text>transcription, as our data showed, is efficiently translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data showed</arg>
                </example>
                <example src="EGRAM" no="407">
                    <text>transcription, as our data showed, is likely to be efficiently translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data showed</arg>
                </example>
                <example src="EGRAM" no="408">
                    <text>transcription, as our data showed, was efficiently translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">transcription, as our data showed</arg>
                </example>
                <example src="EGRAM" no="409">
                    <text>transcription, as shown in our data, is a truncated C-terminal protein translated the first, second, and third transmembrane domains, while exon splicing 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="1">transcription, as shown in our data</arg>
                </example>
                <example src="EGRAM" no="410">
                    <text>translation is able to be efficiently translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while splicing outside exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">translation</arg>
                </example>
                <example src="EGRAM" no="411">
                    <text>translation is efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing outside exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">translation</arg>
                </example>
                <example src="EGRAM" no="412">
                    <text>translation is likely to be efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing outside exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">translation</arg>
                </example>
                <example src="EGRAM" no="413">
                    <text>translation may have been translated efficiently into a truncated C-terminal protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">translation</arg>
                </example>
                <example src="EGRAM" no="414">
                    <text>translation translated efficiently to a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing outside exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">translation</arg>
                </example>
                <example src="EGRAM" no="415">
                    <text>translation was efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing outside exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">translation</arg>
                </example>
                <example src="EGRAM" no="416">
                    <text>translation was efficiently translated into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing outside exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">translation</arg>
                </example>
                <example src="EGRAM" no="417">
                    <text>translation will be translated efficiently into a truncated C-terminal protein containing the first, second, and third transmembrane domains, while splicing outside exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second, and third transmembrane domains</arg>
                    <arg n="1">translation</arg>
                </example>
                <example src="EGRAM" no="418">
                    <text>translation, as our data have shown is able to be efficiently translated into a truncated C-terminal protein containing the first, second and third transmembrane domains, while splicing exons 3 and 4 would produce a protein with five membrane domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a truncated C-terminal protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">translation, as our data have shown</arg>
                </example>
                <example src="EGRAM" no="419">
                    <text>translation, as our data show was translated into a C-terminal truncated protein containing the first, second and third transmembrane domains, while the splicing of exons 3 and 4 would produce a protein with five coverage domains, but without the third and fourth domains present in the ET-AR protein.</text>
                    <arg n="0">a C-terminal truncated protein containing the first, second and third transmembrane domains</arg>
                    <arg n="1">translation, as our data show</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
